0001161697-26-000184.txt : 20260717 0001161697-26-000184.hdr.sgml : 20260717 20260717161555 ACCESSION NUMBER: 0001161697-26-000184 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260715 FILED AS OF DATE: 20260717 DATE AS OF CHANGE: 20260717 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tierney David S CENTRAL INDEX KEY: 0001292636 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 261183925 MAIL ADDRESS: STREET 1: C/O ABLE LABORATORIES, INC. STREET 2: 6 HOLLYWOOD COURT, CN 1013 CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 4 1 form4.xml FORM 4 FOR 07-15-2026 X0609 4 2026-07-15 1 0001369568 CATALYST PHARMACEUTICALS, INC. CPRX 0001292636 Tierney David S false 355 ALHAMBRA CIRCLE, SUITE 801 CORAL GABLES FL 33134 1 0 0 0 0 Common Stock, par value $0.001 per share 2026-07-15 4 D 0 383314 31.50 D 0 D Options to purchase common stock 4.64 2026-07-15 4 D 0 33500 0 D 2026-12-02 Common Stock 33500 0 D Options to purchase common stock 3.42 2026-07-15 4 D 0 30000 0 D 2027-12-30 Common Stock 30000 0 D Options to purchase common stock 7.07 2026-07-15 4 D 0 20000 0 D 2028-12-28 Common Stock 20000 0 D Options to purchase common stock 18.59 2026-07-15 4 D 0 15000 0 D 2029-12-27 Common Stock 15000 0 D Options to purchase common stock 14.15 2026-07-15 4 D 0 29524 0 D 2030-12-08 Common Stock 29524 0 D Options to purchase common stock 21.12 2026-07-15 4 D 0 23248 0 D 2031-11-21 Common Stock 23248 0 D Options to purchase common stock 22.77 2026-07-15 4 D 0 18115 0 D 2032-11-20 Common Stock 18115 0 D Restricted Stock Units 2026-07-15 4 D 0 1414 0 D 2026-12-08 Common Stock 1414 0 D Restricted Stock Units 2026-07-15 4 D 0 1894 0 D 2027-11-21 Common Stock 1894 0 D Restricted Stock Units 2026-07-15 4 D 0 5468 0 D 2028-11-20 Common Stock 5468 0 D The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger") Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. Each Option was fully vested. Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. /s/ David S. Tierney 2026-07-17